An observational study in Sickle Cell Disease, Pregnancy, High Risk and Pregnancy Complications, sponsored by Mount Sinai Hospital, Canada. Enrolling by invitation at 3 sites in 2 countries. Open to female participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-11-27.
Sponsored by Mount Sinai Hospital, Canada · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Anemia, Sickle Cell with a site in Canada — 15 open to participants now, 22 under way, 7 of them phase 3. Anemia, Sickle Cell · Canada.
Among the 55 studies in Anemia, Sickle Cell with a site in Canada, this one is one of 5 that started in 2024, is one of 5 observational ones, reaches primary completion later than 9 of the 21 other live ones, and was the 49th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →15 of the 55 studies in Anemia, Sickle Cell with a site in Canada are open now. Recruiting first, the newest first:
Biossil Inc. · Sites in Canada
Ages 16–50
Yves Pastore · Sites in Canada
Ages 6 mo–18 yrs
Novo Nordisk A/S · Sites in Canada, United States, Australia and 18 more countries
Ages 12+
Novo Nordisk A/S · Sites in Canada, United States, Egypt and 14 more countries
Ages 2+
Bristol-Myers Squibb · Sites in Canada, United States, France and 2 more countries
Ages 18+ · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 16 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 27 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 100 across 297 observational studies indexed under Anemia, Sickle Cell.
Median enrollment 81 across the 49 interventional studies, 300 across the 5 observational. Of the 32 that completed or were terminated, 18 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 55 have an industry lead sponsor. The 10 most frequent:
Mount Sinai Hospital, Canada is the lead sponsor of 158 studies on the registry; 32 are open to participants now.
Mount Sinai Hospital, Canada has 1 study filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Anemia, Sickle Cell with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06612268Phase 3Novo Nordisk A/SA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | 2027-08-27 |
| NCT04018937Emory UniversityEarly Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation | 2026-11 |
| NCT06529042Mount Sinai Hospital, CanadaSCRIPT: Sickle Cell Risk in Pregnancy Tool | 2026-12 |
| NCT06481306Bristol-Myers SquibbA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease | 2027-01-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Anemia, Sickle Cell with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sickle Cell Disease (SCD), common in persons of Black ancestry, affects the shape of hemoglobin, the oxygen-carrying part of red blood cells (RBC). It is characterized by many complications, the most dreaded of which are related to pregnancy - affecting both the mother and unborn child. Compared to those without SCD, people with SCD have more adverse pregnancy outcomes (APO): 6x maternal mortality, 2x preeclampsia \& preterm birth, 4x risk of having a baby not growing well in the womb \& stillbirth. There is also greater need for access to care (7x higher hospitalization often multiple times lasting days to months). Yet up to 30% of SCD pregnancies are uncomplicated.
Treatments in pregnancy are limited and carry risks. A method to distinguish pregnancies at high-risk of APO that may benefit from these potentially risky treatments, from those likely to be uncomplicated, is urgently needed. To meet this need, the investigators developed a calculator to estimate pregnancy complication risk, using single-centre data. Its accuracy and precision will now be evaluated with international information from several centers by testing the calculator, and adjusting it as needed, using already available pregnancy-data from study centres in several countries. Those age >16 years, who have a confirmed SCD genotype, pregnancy with one baby, and pregnancy care and birth at a participating study centre will be included. Pregnancy care for the participants will be up to their doctors, with no changes based on the study. SCRIPT - the new tool - will guide future care by predicting who may benefit from specific treatments, reducing harm to low-risk individuals \& will allow selection of high-risk patients for a future trials to determine whether currently available and novel treatments in well-selected patients can improve APO sufficiently to balance treatment-related harms.
Sickle Cell Disease (SCD) is the most common haemoglobinopathy; predominantly affecting persons of African descent(1). In comparison to those without SCD, pregnant persons with SCD have a six-fold higher risk of mortality, twice the risk of preeclampsia and preterm birth, and nearly a four-fold risk of having a small for gestational age infant or experiencing stillbirth(2,3). Furthermore, there is a higher rate of resource utilization in this group, with nearly 50% of pregnancies complicated by at least one antenatal admission and an overall seven-fold higher hospitalization risk compared to pregnancies without SCD(4,5). These admissions are most commonly secondary to vaso-occlusive events or anemia, can occur on multiple occasions, and can last days to months(4,5).
During pregnancy, red blood cell (RBC) transfusion remains the only recommended intervention(6), with some evidence suggesting that prophylactic transfusion may modify adverse pregnancy outcomes (APOs)(7,8), with a possible positive effect on hospitalization rates through decreased complications, though this requires further study. However, transfusion is not without risk. Beyond its typically-feared infectious complications(9), transfusion in SCD is associated with alloimmunization rates of over 30%(10-12), can induce life-threatening hyperhemolysis(13), and will eventually lead to iron overload(14). At the same time, up to 30% of pregnancies in individuals with SCD remain uncomplicated(2,3,15,16).
A tool is thus urgently needed to separate high-risk individuals who would benefit from transfusion from low-risk individuals who would accrue transfusion risks with minimal, if any benefit. Using a single-centre cohort, the investigators developed maternal and fetal risk prediction models, as the first step in permitting the selection of patients most likely to benefit from transfusion(16). Ultimately, a multi-center international randomized controlled trial (RCT) is required to determine the benefits of prophylactic transfusion in this setting; yet, before such an RCT is conceived, the model(s) must be refined and validated with a larger sample to allow for appropriate participant selection.
The investigators proposed a multicenter international cohort study to enhance the predictive capacity and validate the current model(s) within the participating centers. The academic centers (located in Canada, USA, and France), have multi-disciplinary experts dedicated to managing pregnant persons with SCD, and the combination of MFM and Haematology site co-leads provides essential interdisciplinary expertise with synergistic medical and obstetric perspectives.
Once completed, the Sickle Cell Risk In Pregnancy Tool (SCRIPT) will inform medical decisions regarding transfusion and will set the stage for appropriate selection of high-risk individuals for inclusion in an RCT aimed to definitively determine whether prophylactic transfusion in well-selected pregnant individuals with SCD does indeed improve APOs to the degree that would balance its potential associated harms.
Pregnant Individuals with Sickle Cell Disease (HbSS, HbSC, HbS/β0-thalassemia, HbS/β+-thalassemia)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Non-Interventional
Non-Interventional
Presence of Adverse Pregnancy Outcome
Yes, if any of the following events first noted during the pregnancy within the study period: acute anemia (yes, no), cardiac complication (yes, no), pulmonary complication (yes, no), hepatobiliary complication (yes, no), MSK complication (yes, no), splenic complication (yes, no), neurologic complication (yes, no), renal complication (yes, no); multi-organ failure (yes, no), venous thromboembolism (yes, no), vaso-occlusive event with admission (yes, no), red cell transfusion (yes, no), maternal mortality (yes, no), hypertensive disorder of pregnancy (yes, no), preterm birth (yes, no), small for gestational age (yes, no), or perinatal mortality (yes, no); defined based on published classifications.
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Acute Anemia
Yes, if any of: hyperhemolysis \[clinical diagnosis\], acute splenic sequestration; hepatic sequestration, or aplastic crisis; defined based on published classification
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Cardiac Complications
Yes, if any of: congestive heart failure, cardiomyopathy, cardiomegaly, or arrhythmia; defined based on published classification
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Pulmonary Complications
Yes, if any of: acute chest syndrome; pneumonia, or pulmonary hypertension; defined based on published classification
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Hepato-Biliary Complications
Yes, if any of: cholecystitis, cholelithiasis; cholecystectomy; cholestasis of pregnancy, or viral hepatitis; defined based on published classification
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Musculo-Skeletal Complications
Yes, if any of: avascular necrosis, ulcer, myositis, or osteomyelitis; defined based on published classification
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Neurologic Complications
Yes, if any of: silent cerebral infarct, cerebrovascular accident, cerebral aneurysm, transient ischemic attack, or Moya-Moya syndrome; defined based on published classification
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Renal Complications
Yes, if any of: acute kidney injury, proteinuria, pyelonephritis, or hematuria; defined based on published classification
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Multi-Organ Failure
Consultant's opinion in chart note specifying a diagnosis of "MOF" during current study pregnancy; clinical diagnosis
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Venous Thromboembolism
Yes, if any of: deep vein thrombosis, pulmonary embolism, atypical site venous thrombosis, or cerebral venous sinus thrombosis (CVST); defined based on published classification
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Vaso-Occlusive Event with Admission
Vaso-Occlusive Event (VOE): New onset pain lasting \>4 hrs in current study pregnancy, for which there is no explanation other than vaso-occlusion, and which requires presentation for acute care - patient self-report
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Provision of Red Blood Cell Transfusion
Yes, if any of: simple transfusion in pregnancy, exchange transfusion (manual exchange or erythrocytapheresis), or prophylactic transfusion
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Occurrence of Maternal Mortality
Maternal death during current study pregnancy and up to 6 months postpartum
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation) and continuing to 6 months postpartum
Presence of Hypertensive Disorder of Pregnancy
Yes, if any of: Gestational Hypertension (gHTN) \[persistent de novo HTN over 20 weeks' GA in absence of features of preeclampsia\], Pre-eclampsia (PET) \[gHTN + \>1 new onset conditions \>20 weeks GA - proteinuria or maternal organ/uteroplacental dysfunction\], Eclampsia \[new onset seizures in context of pre-eclampsia\]; or HELLP Syndrome \[Evidence of Hemolysis, Elevated Liver Enzymes, Low Platelets in context of pre-eclampsia\]
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Occurrence of Preterm Birth
Preterm birth (\< 37+0 weeks GA) during current study pregnancy
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation)
Presence of Small for Gestational Age (SGA) Size
Birthweight \<10th centile for gestational age
Time frame: At delivery of infant
Occurrence of Perinatal Mortality
Intrauterine fetal demise (IUFD) \[absence of FHR at or after 20 weeks' gestation\] or Neonatal Death (NND) \[death before 28 days of life, following live birth\]
Time frame: During pregnancy (until delivery of infant, up to 42 weeks of gestation) and up to 28 days after birth)
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mount Sinai Hospital, Canada →